IE52535B1
(en)
*
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
US4637905A
(en)
*
|
1982-03-04 |
1987-01-20 |
Batelle Development Corporation |
Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
|
FR2537980B1
(fr)
*
|
1982-12-17 |
1986-12-19 |
Sandoz Sa |
Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
|
US4652443A
(en)
*
|
1983-06-07 |
1987-03-24 |
Japan Atomic Energy Research Institute |
Slow-release composite and process for producing the same
|
CA1196864A
(en)
*
|
1983-06-10 |
1985-11-19 |
Mattheus F.A. Goosen |
Controlled release of injectable and implantable insulin compositions
|
CH656884A5
(de)
*
|
1983-08-26 |
1986-07-31 |
Sandoz Ag |
Polyolester, deren herstellung und verwendung.
|
CH661206A5
(fr)
*
|
1983-09-23 |
1987-07-15 |
Debiopharm Sa |
Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
|
JPS6097918A
(ja)
*
|
1983-11-01 |
1985-05-31 |
Sumitomo Chem Co Ltd |
インタ−フエロン持続性製剤
|
JPS60100516A
(ja)
*
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
JPS60181029A
(ja)
*
|
1984-02-29 |
1985-09-14 |
Toyo Jozo Co Ltd |
徐放性製剤の製法
|
GB8416234D0
(en)
*
|
1984-06-26 |
1984-08-01 |
Ici Plc |
Biodegradable amphipathic copolymers
|
CA1256638A
(en)
*
|
1984-07-06 |
1989-06-27 |
Motoaki Tanaka |
Polymer and its production
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
US4880635B1
(en)
*
|
1984-08-08 |
1996-07-02 |
Liposome Company |
Dehydrated liposomes
|
DE3434345A1
(de)
*
|
1984-09-19 |
1986-03-27 |
Hoechst Ag, 6230 Frankfurt |
Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
|
ATE61935T1
(de)
*
|
1985-02-07 |
1991-04-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung von mikrokapseln.
|
NZ216122A
(en)
*
|
1985-05-10 |
1989-07-27 |
Univ Melbourne |
Stimulating ovulation in mares by administering gonadotrophin-releasing hormones
|
US5137874A
(en)
*
|
1985-07-29 |
1992-08-11 |
American Cyanamid Co. |
Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
|
US5169633A
(en)
*
|
1985-07-29 |
1992-12-08 |
American Cyanamid Company |
Continuous release phenylethanolamine derivative compositions
|
US5059422A
(en)
*
|
1985-07-29 |
1991-10-22 |
American Cyanamid Company |
Continuous release phenylethanolamine derivative compositions
|
US5102872A
(en)
*
|
1985-09-20 |
1992-04-07 |
Cetus Corporation |
Controlled-release formulations of interleukin-2
|
US4643191A
(en)
*
|
1985-11-29 |
1987-02-17 |
Ethicon, Inc. |
Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
|
JPH0725688B2
(ja)
*
|
1986-03-31 |
1995-03-22 |
住友製薬株式会社 |
Csf徐放性製剤
|
GB8609537D0
(en)
*
|
1986-04-18 |
1986-05-21 |
Ici Plc |
Polyesters
|
EP0248531A3
(en)
*
|
1986-05-02 |
1988-09-28 |
Southern Research Institute |
Encapsulated nucleic acids
|
CA1257199A
(en)
*
|
1986-05-20 |
1989-07-11 |
Paul Y. Wang |
Preparation containing bioactive macromolecular substance for multi-months release in vivo
|
US4962091A
(en)
*
|
1986-05-23 |
1990-10-09 |
Syntex (U.S.A.) Inc. |
Controlled release of macromolecular polypeptides
|
US6150328A
(en)
|
1986-07-01 |
2000-11-21 |
Genetics Institute, Inc. |
BMP products
|
JPH0725689B2
(ja)
*
|
1986-10-07 |
1995-03-22 |
中外製薬株式会社 |
顆粒球コロニ−刺激因子を含有する徐放性製剤
|
US6024983A
(en)
*
|
1986-10-24 |
2000-02-15 |
Southern Research Institute |
Composition for delivering bioactive agents for immune response and its preparation
|
US4981696A
(en)
*
|
1986-12-22 |
1991-01-01 |
E. I. Du Pont De Nemours And Company |
Polylactide compositions
|
DE3701625A1
(de)
*
|
1987-01-21 |
1988-08-04 |
Boehringer Ingelheim Kg |
Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
|
DE3710175A1
(de)
*
|
1987-02-12 |
1988-08-25 |
Hoechst Ag |
Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
|
AU606383B2
(en)
*
|
1987-03-06 |
1991-02-07 |
Research Triangle Institute |
Polymer blends for selective biodegradability
|
US5028430A
(en)
*
|
1987-05-08 |
1991-07-02 |
Syntex (U.S.A.) Inc. |
Delivery systems for the controlled administration of LHRH analogs
|
US5000886A
(en)
*
|
1987-05-26 |
1991-03-19 |
American Cyanamid Company |
Silicone-hardened pharmaceutical microcapsules and process of making the same
|
GB8716324D0
(en)
*
|
1987-07-10 |
1987-08-19 |
Sandoz Ltd |
Organic compounds
|
DE3845000C2
(de)
*
|
1987-07-10 |
1998-11-19 |
Novartis Ag |
Anwendung von Octreotid zur Behandlung von Brustkrebs
|
US4866226A
(en)
*
|
1987-07-13 |
1989-09-12 |
Mitsubishi Denki Kabushiki Kaisha |
Multi-phase circuit breaker employing arc extinguishing apparatus
|
JPH0613602B2
(ja)
*
|
1987-07-14 |
1994-02-23 |
三井東圧化学株式会社 |
d▲l▼−乳酸−グリコール酸共重合物の製造方法
|
US4897268A
(en)
*
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
US5212154A
(en)
*
|
1987-08-14 |
1993-05-18 |
Akzo N.V. |
Preparation for treating complications in diabetes
|
US5457093A
(en)
*
|
1987-09-18 |
1995-10-10 |
Ethicon, Inc. |
Gel formulations containing growth factors
|
NZ226171A
(en)
*
|
1987-09-18 |
1990-06-26 |
Ethicon Inc |
Gel formulation containing polypeptide growth factor
|
GB2209937B
(en)
*
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
US5187150A
(en)
*
|
1987-10-14 |
1993-02-16 |
Debiopharm S.A. |
Polyester-based composition for the controlled release of polypeptide medicinal substances
|
JP2670680B2
(ja)
*
|
1988-02-24 |
1997-10-29 |
株式会社ビーエムジー |
生理活性物質含有ポリ乳酸系微小球およびその製造法
|
US4902515A
(en)
*
|
1988-04-28 |
1990-02-20 |
E. I. Dupont De Nemours And Company |
Polylactide compositions
|
FR2634770B1
(fr)
*
|
1988-07-29 |
1990-10-05 |
Rhone Poulenc Chimie |
Composition polyester erodable contenant de l'iode pour le traitement des eaux
|
US5180765A
(en)
*
|
1988-08-08 |
1993-01-19 |
Biopak Technology, Ltd. |
Biodegradable packaging thermoplastics from lactides
|
US5502158A
(en)
*
|
1988-08-08 |
1996-03-26 |
Ecopol, Llc |
Degradable polymer composition
|
US5252642A
(en)
*
|
1989-03-01 |
1993-10-12 |
Biopak Technology, Ltd. |
Degradable impact modified polyactic acid
|
US5424346A
(en)
*
|
1988-08-08 |
1995-06-13 |
Ecopol, Llc |
Biodegradable replacement of crystal polystyrene
|
US5444113A
(en)
*
|
1988-08-08 |
1995-08-22 |
Ecopol, Llc |
End use applications of biodegradable polymers
|
US6323307B1
(en)
|
1988-08-08 |
2001-11-27 |
Cargill Dow Polymers, Llc |
Degradation control of environmentally degradable disposable materials
|
US5216050A
(en)
*
|
1988-08-08 |
1993-06-01 |
Biopak Technology, Ltd. |
Blends of polyactic acid
|
US5250584A
(en)
*
|
1988-08-31 |
1993-10-05 |
G-C Dental Industrial Corp. |
Periodontium-regenerative materials
|
US5633002A
(en)
*
|
1988-10-04 |
1997-05-27 |
Boehringer Ingelheim Gmbh |
Implantable, biodegradable system for releasing active substance
|
US5247013A
(en)
*
|
1989-01-27 |
1993-09-21 |
Mitsui Toatsu Chemicals, Inc. |
Biocompatible polyester and production thereof
|
US4990336A
(en)
*
|
1989-02-08 |
1991-02-05 |
Biosearch, Inc. |
Sustained release dosage form
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
EP0462189B1
(en)
*
|
1989-03-10 |
1995-09-27 |
Endorecherche Inc. |
Combination therapy for treatment of estrogen sensitive diseases
|
NZ234227A
(en)
*
|
1989-06-30 |
1991-08-27 |
Smithkline Beecham Corp |
Delayed release dosage form
|
WO1991000733A1
(en)
*
|
1989-07-07 |
1991-01-24 |
Endorecherche Inc. |
Method of treatment of androgen-related diseases
|
HU221294B1
(en)
*
|
1989-07-07 |
2002-09-28 |
Novartis Ag |
Process for producing retarde compositions containing the active ingredient in a polymeric carrier
|
PH30995A
(en)
*
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
US5538739A
(en)
*
|
1989-07-07 |
1996-07-23 |
Sandoz Ltd. |
Sustained release formulations of water soluble peptides
|
EP0485392B1
(en)
*
|
1989-07-07 |
1998-09-09 |
Endorecherche Inc. |
Androgen derivatives for use in the inhibition of sex steroid activity
|
US5225205A
(en)
*
|
1989-07-28 |
1993-07-06 |
Debiopharm S.A. |
Pharmaceutical composition in the form of microparticles
|
CH679207A5
(hu)
*
|
1989-07-28 |
1992-01-15 |
Debiopharm Sa |
|
US5439688A
(en)
*
|
1989-07-28 |
1995-08-08 |
Debio Recherche Pharmaceutique S.A. |
Process for preparing a pharmaceutical composition
|
DE59003337D1
(de)
*
|
1989-10-16 |
1993-12-09 |
Danubia Petrochem Polymere |
Pressling mit retardierter Wirkstofffreisetzung.
|
US5126147A
(en)
*
|
1990-02-08 |
1992-06-30 |
Biosearch, Inc. |
Sustained release dosage form
|
US6517859B1
(en)
|
1990-05-16 |
2003-02-11 |
Southern Research Institute |
Microcapsules for administration of neuroactive agents
|
ES2185615T3
(es)
*
|
1990-05-16 |
2003-05-01 |
Southern Res Inst |
Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.
|
CA2046830C
(en)
*
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
US5620959A
(en)
*
|
1990-07-31 |
1997-04-15 |
Glaxo Wellcome Inc. |
Bombesin antagonists
|
GB9016885D0
(en)
*
|
1990-08-01 |
1990-09-12 |
Scras |
Sustained release pharmaceutical compositions
|
US6353030B1
(en)
|
1990-08-01 |
2002-03-05 |
Novartis Ag |
Relating to organic compounds
|
ZA918168B
(en)
*
|
1990-10-16 |
1993-04-14 |
Takeda Chemical Industries Ltd |
Prolonged release preparation and polymers thereof.
|
US5342557A
(en)
*
|
1990-11-27 |
1994-08-30 |
United States Surgical Corporation |
Process for preparing polymer particles
|
US7285531B1
(en)
*
|
1991-04-10 |
2007-10-23 |
Acorda Therapeutics, Inc. |
Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
|
US5486362A
(en)
*
|
1991-05-07 |
1996-01-23 |
Dynagen, Inc. |
Controlled, sustained release delivery system for treating drug dependency
|
US5403595A
(en)
*
|
1991-05-07 |
1995-04-04 |
Dynagen, Inc. |
Controlled, sustained release delivery system for smoking cessation
|
HU222501B1
(hu)
*
|
1991-06-28 |
2003-07-28 |
Endorecherche Inc. |
MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
CH683149A5
(fr)
*
|
1991-07-22 |
1994-01-31 |
Debio Rech Pharma Sa |
Procédé pour la préparation de microsphères en matériau polymère biodégradable.
|
ATE238417T1
(de)
|
1991-11-04 |
2003-05-15 |
Inst Genetics Llc |
Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
|
US6013853A
(en)
*
|
1992-02-14 |
2000-01-11 |
The University Of Texas System |
Continuous release polymeric implant carrier
|
US5876452A
(en)
*
|
1992-02-14 |
1999-03-02 |
Board Of Regents, University Of Texas System |
Biodegradable implant
|
US5656297A
(en)
*
|
1992-03-12 |
1997-08-12 |
Alkermes Controlled Therapeutics, Incorporated |
Modulated release from biocompatible polymers
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
WO1993017668A1
(en)
*
|
1992-03-12 |
1993-09-16 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release acth containing microspheres
|
US5429822A
(en)
*
|
1992-03-13 |
1995-07-04 |
Cambridge Scientific, Inc. |
Biodegradable bursting release system
|
US5780051A
(en)
*
|
1992-04-02 |
1998-07-14 |
Dynagen, Inc. |
Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
|
WO1993023053A1
(en)
*
|
1992-05-21 |
1993-11-25 |
Endorecherche Inc. |
INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY
|
GB9211268D0
(en)
*
|
1992-05-28 |
1992-07-15 |
Ici Plc |
Salts of basic peptides with carboxyterminated polyesters
|
US20030035845A1
(en)
*
|
1992-06-11 |
2003-02-20 |
Zale Stephen E. |
Composition for sustained release of non-aggregated erythropoietin
|
US5716644A
(en)
*
|
1992-06-11 |
1998-02-10 |
Alkermes, Inc. |
Composition for sustained release of non-aggregated erythropoietin
|
US5674534A
(en)
*
|
1992-06-11 |
1997-10-07 |
Alkermes, Inc. |
Composition for sustained release of non-aggregated erythropoietin
|
JP2651320B2
(ja)
*
|
1992-07-16 |
1997-09-10 |
田辺製薬株式会社 |
徐放性マイクロスフェア製剤の製造方法
|
FR2693905B1
(fr)
*
|
1992-07-27 |
1994-09-02 |
Rhone Merieux |
Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
|
US5922340A
(en)
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
US5281419A
(en)
*
|
1992-09-28 |
1994-01-25 |
Thomas Jefferson University |
Biodegradable drug delivery system for the prevention and treatment of osteomyelitis
|
WO1994012158A1
(en)
*
|
1992-12-02 |
1994-06-09 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release growth hormone containing microspheres
|
UA61046C2
(en)
|
1992-12-07 |
2003-11-17 |
Takeda Chemical Industries Ltd |
Sustained-release preparation and method for its manufacture
|
TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US5672659A
(en)
*
|
1993-01-06 |
1997-09-30 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
ATE236655T1
(de)
*
|
1993-01-06 |
2003-04-15 |
Kinerton Ltd |
Ionische molekularkonjugate von bioabbaubaren polyestern und bioaktiven polypeptiden
|
US5863985A
(en)
*
|
1995-06-29 |
1999-01-26 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US6221958B1
(en)
|
1993-01-06 |
2001-04-24 |
Societe De Conseils De Recherches Et D'applications Scientifiques, Sas |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US5456917A
(en)
*
|
1993-04-12 |
1995-10-10 |
Cambridge Scientific, Inc. |
Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
|
US5569467A
(en)
*
|
1993-05-15 |
1996-10-29 |
Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) |
Process for the preparation of microballs and microballs thus obtained
|
GB9310030D0
(en)
*
|
1993-05-15 |
1993-06-30 |
Scras |
Dry processed particles and process for the preparation of the same
|
US5635216A
(en)
*
|
1993-12-16 |
1997-06-03 |
Eli Lilly And Company |
Microparticle compositions containing peptides, and methods for the preparation thereof
|
US6440457B1
(en)
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
AU689786B2
(en)
*
|
1993-06-30 |
1998-04-09 |
Genentech Inc. |
Method for preparing liposomes
|
JP3822232B2
(ja)
|
1993-08-30 |
2006-09-13 |
ベイラー・カレッジ・オブ・メディシン |
老化細胞由来dna合成阻害因子
|
US6291206B1
(en)
|
1993-09-17 |
2001-09-18 |
Genetics Institute, Inc. |
BMP receptor proteins
|
US5496923A
(en)
*
|
1993-09-20 |
1996-03-05 |
Mitsui Toatsu Chemicals, Inc. |
Purification process of aliphatic polyester
|
US5643605A
(en)
*
|
1993-10-25 |
1997-07-01 |
Genentech, Inc. |
Methods and compositions for microencapsulation of adjuvants
|
US6080429A
(en)
*
|
1993-10-25 |
2000-06-27 |
Genentech, Inc. |
Method for drying microspheres
|
US6913767B1
(en)
|
1993-10-25 |
2005-07-05 |
Genentech, Inc. |
Compositions for microencapsulation of antigens for use as vaccines
|
WO1995016035A2
(en)
|
1993-12-07 |
1995-06-15 |
Genetics Institute, Inc. |
Bmp-12, bmp-13 and tendon-inducing compositions thereof
|
US5962427A
(en)
*
|
1994-02-18 |
1999-10-05 |
The Regent Of The University Of Michigan |
In vivo gene transfer methods for wound healing
|
US20020193338A1
(en)
*
|
1994-02-18 |
2002-12-19 |
Goldstein Steven A. |
In vivo gene transfer methods for wound healing
|
US6074840A
(en)
|
1994-02-18 |
2000-06-13 |
The Regents Of The University Of Michigan |
Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
|
US5763416A
(en)
*
|
1994-02-18 |
1998-06-09 |
The Regent Of The University Of Michigan |
Gene transfer into bone cells and tissues
|
US5942496A
(en)
*
|
1994-02-18 |
1999-08-24 |
The Regent Of The University Of Michigan |
Methods and compositions for multiple gene transfer into bone cells
|
DE4406172C2
(de)
*
|
1994-02-25 |
2003-10-02 |
Sanol Arznei Schwarz Gmbh |
Polyester
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US5607686A
(en)
*
|
1994-11-22 |
1997-03-04 |
United States Surgical Corporation |
Polymeric composition
|
AU4611496A
(en)
*
|
1995-02-28 |
1996-09-18 |
Innapharma, Inc. |
Elcatonin controlled release microsphere formulation for treatment of osteoporosis
|
US6479457B2
(en)
*
|
1995-06-06 |
2002-11-12 |
Kinerton Limited |
Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
|
US5665702A
(en)
*
|
1995-06-06 |
1997-09-09 |
Biomeasure Incorporated |
Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
|
US5747058A
(en)
*
|
1995-06-07 |
1998-05-05 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
US5968542A
(en)
*
|
1995-06-07 |
1999-10-19 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system as a device
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
US6413536B1
(en)
*
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
WO1996041616A1
(en)
|
1995-06-09 |
1996-12-27 |
Euro-Celtique, S.A. |
Formulations and methods for providing prolonged local anesthesia
|
US5955574A
(en)
|
1995-07-13 |
1999-09-21 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. |
Analogs of parathyroid hormone
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
AU6710196A
(en)
*
|
1995-08-29 |
1997-03-19 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polyhydroxy carboxylic acid
|
US5916597A
(en)
*
|
1995-08-31 |
1999-06-29 |
Alkermes Controlled Therapeutics, Inc. |
Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
|
US5942253A
(en)
*
|
1995-10-12 |
1999-08-24 |
Immunex Corporation |
Prolonged release of GM-CSF
|
CA2192773C
(en)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Production of sustained-release preparation for injection
|
US5980945A
(en)
*
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
EP0823448A4
(en)
*
|
1996-02-23 |
1998-08-12 |
Kyowa Hakko Kogyo Kk |
METHOD FOR PRODUCING POLYHYDROXYCARBOXYLIC ACID
|
US5747060A
(en)
*
|
1996-03-26 |
1998-05-05 |
Euro-Celtique, S.A. |
Prolonged local anesthesia with colchicine
|
IE960308A1
(en)
*
|
1996-04-23 |
1997-11-05 |
Kinerton Ltd |
Sustained release ionic conjugate
|
RU2165942C2
(ru)
*
|
1996-04-23 |
2001-04-27 |
Кинертон Лимитид |
Биоразрушаемый сложный полиэфир и способ его получения (варианты)
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US5766877A
(en)
|
1996-05-10 |
1998-06-16 |
Amgen Inc. |
Genes encoding art, an agouti-related transcript
|
US5817343A
(en)
*
|
1996-05-14 |
1998-10-06 |
Alkermes, Inc. |
Method for fabricating polymer-based controlled-release devices
|
EP0954301A4
(en)
|
1996-06-24 |
2006-03-08 |
Euro Celtique Sa |
SAFE METHODS OF LOCAL ANESTHESIA
|
US6046187A
(en)
*
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
US5952455A
(en)
*
|
1996-10-11 |
1999-09-14 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing polyhydroxycarboxylic acid
|
CA2665133A1
(en)
|
1996-10-25 |
1998-05-07 |
Human Genome Sciences, Inc. |
Neutrokine .alpha.
|
DK0839525T3
(da)
|
1996-10-31 |
2004-11-29 |
Takeda Pharmaceutical |
Præparat med forlænget frigivelse
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
US5919656A
(en)
|
1996-11-15 |
1999-07-06 |
Amgen Canada Inc. |
Genes encoding telomerase protein 1
|
US20020111603A1
(en)
|
1996-12-02 |
2002-08-15 |
Societe De Conseils De Recherches Et D'application |
Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
|
US7138511B1
(en)
|
1997-01-28 |
2006-11-21 |
The Regents Of The University Of California |
Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6475724B1
(en)
|
1997-01-28 |
2002-11-05 |
The Regents Of The University Of California |
Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6171788B1
(en)
|
1997-01-28 |
2001-01-09 |
The Regents Of The University Of California |
Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US7235524B2
(en)
*
|
1997-01-31 |
2007-06-26 |
Applied Research System Ars Holding N.V. |
Medicaments for initiating ovulation
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
US6071982A
(en)
*
|
1997-04-18 |
2000-06-06 |
Cambridge Scientific, Inc. |
Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
ATE487737T1
(de)
|
1997-05-30 |
2010-11-15 |
Human Genome Sciences Inc |
32 humane sekretierte proteine
|
US6867181B1
(en)
|
1997-06-02 |
2005-03-15 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
EP1009390A4
(en)
|
1997-07-02 |
2004-05-06 |
Euro Celtique Sa |
LONG-EFFECT ANESTHESIA INJECTED IN JOINT AND BODY SPACES
|
US6994851B1
(en)
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
ATE417927T1
(de)
|
1997-07-30 |
2009-01-15 |
Univ Emory |
Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
EP1015488B1
(en)
|
1997-09-17 |
2009-09-09 |
Human Genome Sciences, Inc. |
Interleukin-17 receptor-like protein
|
AU1384199A
(en)
|
1997-11-07 |
1999-05-31 |
Chiron Corporation |
Method for producing igf-1 sustained-release formulations
|
US6372880B1
(en)
|
1997-12-25 |
2002-04-16 |
Mitsui Chemicals, Inc. |
Copolymer and process for preparing the same
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
WO1999038536A1
(en)
*
|
1998-01-29 |
1999-08-05 |
Poly-Med Inc. |
Absorbable microparticles
|
AU740493B2
(en)
|
1998-01-29 |
2001-11-08 |
Kinerton Limited |
Process for making absorbable microparticles
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
US20030180368A1
(en)
*
|
1998-03-14 |
2003-09-25 |
Cenes Drug Delivery Limited |
Production of microparticles
|
DK1064382T3
(da)
|
1998-03-17 |
2008-12-08 |
Genentech Inc |
Homologe polypeptider til VEGF og BMP1
|
WO1999047538A1
(en)
|
1998-03-19 |
1999-09-23 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
US7662409B2
(en)
*
|
1998-09-25 |
2010-02-16 |
Gel-Del Technologies, Inc. |
Protein matrix materials, devices and methods of making and using thereof
|
US20030007991A1
(en)
*
|
1998-09-25 |
2003-01-09 |
Masters David B. |
Devices including protein matrix materials and methods of making and using thereof
|
SG121778A1
(en)
|
1998-10-09 |
2006-05-26 |
Univ Emory |
Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
US6565874B1
(en)
*
|
1998-10-28 |
2003-05-20 |
Atrix Laboratories |
Polymeric delivery formulations of leuprolide with improved efficacy
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
EP1144013B1
(en)
*
|
1998-11-02 |
2007-03-21 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Lactone bearing absorbable polymers
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
US6365173B1
(en)
|
1999-01-14 |
2002-04-02 |
Efrat Biopolymers Ltd. |
Stereocomplex polymeric carriers for drug delivery
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US6727224B1
(en)
|
1999-02-01 |
2004-04-27 |
Genetics Institute, Llc. |
Methods and compositions for healing and repair of articular cartilage
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
HUP0105337A3
(en)
|
1999-02-03 |
2011-01-28 |
Amgen Inc |
Polypeptides involved in immune response
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
EP2286792A1
(en)
|
1999-02-26 |
2011-02-23 |
Novartis Vaccines and Diagnostics, Inc. |
Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
|
JP2002537769A
(ja)
|
1999-02-26 |
2002-11-12 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒトエンドカインαおよび使用方法
|
WO2000054797A2
(en)
|
1999-03-17 |
2000-09-21 |
Novartis Ag |
Pharmaceutical compositions comprising tgf-beta
|
AU3770800A
(en)
|
1999-03-26 |
2000-10-16 |
Amgen, Inc. |
Beta secretase genes and polypeptides
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
US20030166561A1
(en)
*
|
1999-06-18 |
2003-09-04 |
Cooper Garth J. S. |
Peptide
|
EP2339003A3
(en)
|
1999-06-28 |
2011-10-19 |
Genentech, Inc. |
Apo-2 ligand substitutional variants
|
US7713739B1
(en)
|
2000-11-17 |
2010-05-11 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticle-based transfection and activation of dendritic cells
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
JP4703926B2
(ja)
|
1999-10-15 |
2011-06-15 |
ジェネティクス インスティテュート,エルエルシー |
骨形成蛋白をデリバリーするためのヒアルロン酸の処方
|
US7078382B1
(en)
|
1999-11-02 |
2006-07-18 |
Genentech, Inc. |
Modulation of eNOS activity and therapeutic uses thereof
|
US6682754B2
(en)
*
|
1999-11-24 |
2004-01-27 |
Willmar Poultry Company, Inc. |
Ovo delivery of an immunogen containing implant
|
US6465425B1
(en)
*
|
2000-02-10 |
2002-10-15 |
Alkermes Controlled Therapeutics, Inc. |
Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
DK1265630T3
(da)
*
|
2000-03-24 |
2006-10-09 |
Genentech Inc |
Anvendelse af insulin til behandling af brusksygdomme
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
EP1276756A4
(en)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
MXPA02011675A
(es)
*
|
2000-05-24 |
2004-07-30 |
Jordan Loyal Holtzman |
Agentes y metodos para incrementar los niveles de chaperonin en el cerebro.
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2792747A1
(en)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2168980A1
(en)
|
2000-06-23 |
2010-03-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
PT2077279E
(pt)
|
2000-06-28 |
2012-09-14 |
Amgen Inc |
Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
|
JP5046447B2
(ja)
*
|
2000-08-07 |
2012-10-10 |
和光純薬工業株式会社 |
乳酸重合体及びその製造方法
|
US6362308B1
(en)
|
2000-08-10 |
2002-03-26 |
Alkermes Controlled Therapeutics Inc. Ii |
Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
|
US6565888B1
(en)
|
2000-08-23 |
2003-05-20 |
Alkermes Controlled Therapeutics, Inc. |
Methods and compositions for the targeted delivery of biologically active agents
|
EP1317283B1
(en)
|
2000-09-14 |
2011-07-06 |
Biogen Idec MA Inc. |
Tweak receptor agonists as anti-angiogenic agents
|
AU2001296770A1
(en)
*
|
2000-10-06 |
2002-04-15 |
Durect Corporation |
Devices and methods for management of inflammation
|
DE10055742B4
(de)
|
2000-11-10 |
2006-05-11 |
Schwarz Pharma Ag |
Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
|
US8470359B2
(en)
|
2000-11-13 |
2013-06-25 |
Qlt Usa, Inc. |
Sustained release polymer
|
JP2006500115A
(ja)
|
2000-11-16 |
2006-01-05 |
マイクロスフエリツクス・エル・エル・シー |
密封小線源治療用の可撓性および/または弾性シードまたはストランド
|
AU2002217969B2
(en)
|
2000-11-28 |
2007-12-20 |
Amgen Canada Inc. |
Polypeptides involved in immune response
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
US6599627B2
(en)
|
2000-12-13 |
2003-07-29 |
Purdue Research Foundation |
Microencapsulation of drugs by solvent exchange
|
JP2004521111A
(ja)
*
|
2001-01-25 |
2004-07-15 |
ユーロ−セルティーク,エス.エイ. |
局所麻酔薬および使用法
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
WO2002099037A2
(en)
|
2001-06-01 |
2002-12-12 |
Wyeth |
Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
TWI267378B
(en)
|
2001-06-08 |
2006-12-01 |
Wyeth Corp |
Calcium phosphate delivery vehicles for osteoinductive proteins
|
CA2451187C
(en)
*
|
2001-06-22 |
2012-08-14 |
Southern Biosystems, Inc. |
Zero-order prolonged release coaxial implants
|
EP2087908B1
(en)
|
2001-06-26 |
2018-05-30 |
Amgen Inc. |
Antibodies to opgl
|
AR034641A1
(es)
|
2001-06-29 |
2004-03-03 |
Takeda Pharmaceutical |
Composicion de liberacion controlada y metodo para producirla
|
AU2002335657A1
(en)
|
2001-08-24 |
2003-03-10 |
Neuronz Biosciences, Inc. |
Neural regeneration peptide and methods for their use in treatment of brain damage
|
PL368972A1
(en)
|
2001-08-29 |
2005-04-04 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
AU2002325712C1
(en)
*
|
2001-08-30 |
2008-07-31 |
Stem Cell Therapeutics Inc. |
Differentiation of neural stem cells and therapeutic use theeof
|
GB0122113D0
(en)
*
|
2001-09-11 |
2001-10-31 |
Astrazeneca Ab |
Composition
|
AR036401A1
(es)
*
|
2001-09-14 |
2004-09-08 |
Stem Cell Therapeutics Inc |
Incremento de la cantidad de celulas madre neuronales inducido por prolactina.
|
US20030054551A1
(en)
*
|
2001-09-18 |
2003-03-20 |
Stem Cell Therapeutics Inc. |
Effect of growth hormone and IGF-1 on neural stem cells
|
ES2320979T3
(es)
|
2001-09-24 |
2009-06-01 |
Imperial Innovations Limited |
Pyy-36 para la reduccion o prevencion de la obesidad.
|
US20040186051A1
(en)
|
2001-10-02 |
2004-09-23 |
Kelley Robert F |
Apo-2 ligand variants and uses thereof
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
EP2316485A1
(en)
|
2001-10-12 |
2011-05-04 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
ES2351786T3
(es)
|
2001-11-13 |
2011-02-10 |
Genentech, Inc. |
Formulaciones con ligando apo2/trail y usos de las mismas.
|
ES2329346T3
(es)
*
|
2001-11-14 |
2009-11-25 |
Durect Corporation |
Composicion de deposito inyectable.
|
HK1077740A1
(en)
|
2001-12-20 |
2006-02-24 |
Ct Ingenieria Genetica Biotech |
Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
|
ES2545090T3
(es)
|
2001-12-21 |
2015-09-08 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina y GCSF
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
AU2003201998C1
(en)
|
2002-01-10 |
2012-10-25 |
Imperial Innovations Limited |
Modification of feeding behavior
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
AU2003225895A1
(en)
*
|
2002-03-19 |
2003-10-08 |
Purdue Research Foundation |
Microencapsulation using ultrasonic atomizers
|
WO2003086289A2
(en)
|
2002-04-05 |
2003-10-23 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
EP1500665B1
(en)
|
2002-04-15 |
2011-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
METHODS FOR CONSTRUCTING scDb LIBRARIES
|
DE60327199D1
(de)
|
2002-04-26 |
2009-05-28 |
Chugai Pharmaceutical Co Ltd |
Verfahren zum screening auf agonistische antikörper
|
AU2003225212A1
(en)
|
2002-04-29 |
2003-11-17 |
Gel-Del Technologies, Inc. |
Biomatrix structural containment and fixation systems and methods of use thereof
|
WO2003099320A1
(en)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
DE10227232A1
(de)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
CA2489348A1
(en)
|
2002-06-24 |
2003-12-31 |
Genentech, Inc. |
Apo-2 ligand/trail variants and uses thereof
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
EP1546198A1
(en)
*
|
2002-07-31 |
2005-06-29 |
Stem Cell Therapeutics Inc. |
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
US8075585B2
(en)
*
|
2002-08-29 |
2011-12-13 |
Stryker Corporation |
Device and method for treatment of a vascular defect
|
CA2497884C
(en)
|
2002-09-06 |
2013-10-22 |
Brian Varnum |
Therapeutic human anti-il-1r1 monoclonal antibody
|
AU2003285874A1
(en)
|
2002-10-16 |
2004-05-04 |
Amgen Inc. |
HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
|
US20040086532A1
(en)
*
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
WO2004046331A2
(en)
|
2002-11-15 |
2004-06-03 |
Idenix (Cayman) Limited |
2’-branched nucleosides and flaviviridae mutation
|
CA2508375C
(en)
|
2002-12-02 |
2014-05-27 |
Abgenix, Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
SI2218448T1
(sl)
*
|
2002-12-13 |
2016-01-29 |
Durect Corporation |
Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
|
US7022481B2
(en)
|
2002-12-19 |
2006-04-04 |
Rosetta Inpharmatics Llc |
Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
|
WO2004060911A2
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP1440992A1
(fr)
*
|
2003-01-21 |
2004-07-28 |
Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) |
Système catalytique de (co)polymérisation du lactide et du glycolide
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
SG168407A1
(en)
|
2003-01-28 |
2011-02-28 |
Ironwood Pharmaceuticals Inc |
Methods and compositions for the treatment of gastrointestinal disorders
|
GB0304726D0
(en)
*
|
2003-03-01 |
2003-04-02 |
Ardana Bioscience Ltd |
New Process
|
CA2515583C
(en)
|
2003-03-07 |
2015-07-14 |
Diversa Corporation |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
造血促進のためのbv8及び/又はeg−vegfの使用
|
CA2518667C
(en)
*
|
2003-03-14 |
2011-07-19 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
|
US20060076295A1
(en)
*
|
2004-03-15 |
2006-04-13 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
|
WO2004084823A2
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
BRPI0408501A
(pt)
|
2003-03-19 |
2006-03-14 |
Biogen Idec Inc |
proteìna de ligação ao receptor nogo
|
ES2383752T3
(es)
|
2003-05-15 |
2012-06-26 |
Trustees Of Tufts College |
Analogos estables de GLP-1
|
WO2004103313A2
(en)
|
2003-05-20 |
2004-12-02 |
The American National Red Cross |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tpa) and tpa inhibitors useful therein
|
KR20140142311A
(ko)
|
2003-06-27 |
2014-12-11 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
JP2008518881A
(ja)
|
2003-07-18 |
2008-06-05 |
オークウッド ラボラトリーズ,エル.エル.シー. |
高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
|
RS53476B
(en)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
US8541051B2
(en)
*
|
2003-08-14 |
2013-09-24 |
Halliburton Energy Services, Inc. |
On-the fly coating of acid-releasing degradable material onto a particulate
|
US9149440B2
(en)
*
|
2003-09-02 |
2015-10-06 |
University Of South Florida |
Nanoparticles for drug-delivery
|
GB0320806D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
PT2274978E
(pt)
|
2003-09-12 |
2015-07-09 |
Ipsen Biopharmaceuticals Inc |
Métodos para tratamento da deficiência do fator de crescimento de tipo insulina i (igf-i)
|
EP1675608B1
(en)
|
2003-09-12 |
2007-03-21 |
Wyeth |
Injectable calcium phosphate solid rods for delivery of osteogenic proteins
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
US20050080313A1
(en)
*
|
2003-10-10 |
2005-04-14 |
Stewart Daren L. |
Applicator for radiation treatment of a cavity
|
US7783006B2
(en)
*
|
2003-10-10 |
2010-08-24 |
Xoft, Inc. |
Radiation treatment using x-ray source
|
US7309232B2
(en)
*
|
2003-10-10 |
2007-12-18 |
Dentigenix Inc. |
Methods for treating dental conditions using tissue scaffolds
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
AU2004287431B2
(en)
|
2003-10-27 |
2010-03-11 |
Amgen Inc. |
Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
|
JP5105578B2
(ja)
|
2003-11-05 |
2012-12-26 |
サーコード バイオサイエンス インコーポレイテッド |
細胞接着のモジュレーター
|
EP1711159B1
(en)
*
|
2003-12-30 |
2013-03-20 |
Durect Corporation |
Solid implants containing a block copolymer for controlled release of a gnrh compound
|
CN100534527C
(zh)
*
|
2003-12-30 |
2009-09-02 |
杜雷科特公司 |
用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
|
EP1708734A4
(en)
*
|
2004-01-07 |
2009-06-17 |
Trimeris Inc |
PEPTIDES DERIVED FROM HIV GP41 HR2 AND THEIR USE IN THERAPY TO INHIBIT THE TRANSMISSION OF HUMAN IMMUNODICIENCY VIRUS
|
NZ548256A
(en)
|
2004-02-02 |
2010-02-26 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
US20070066525A1
(en)
*
|
2004-02-04 |
2007-03-22 |
Lee John C |
Compositions and therapeutic methods using morphogenic proteins
|
US7846898B2
(en)
|
2004-02-13 |
2010-12-07 |
Stem Cell Therapeutics Corp. |
Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
|
US7807176B2
(en)
|
2004-03-19 |
2010-10-05 |
Genomidea, Inc. |
Polypeptide promoting vascular endothelial cell growth
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
CA2560742A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
WO2005115992A1
(en)
|
2004-05-23 |
2005-12-08 |
Housey Pharmaceuticals, Inc. |
Theramutein modulators
|
CA2567405A1
(en)
|
2004-05-25 |
2005-12-08 |
Stryker Corporation |
Use of morphogenic proteins for treating cartilage defects
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
EP1758999B1
(en)
|
2004-06-22 |
2011-03-09 |
The Board Of Trustees Of The University Of Illinois |
METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
|
PL1776136T3
(pl)
|
2004-06-24 |
2013-03-29 |
Biogen Ma Inc |
Leczenie stanów związanych z demielinizacją
|
US20080280973A1
(en)
*
|
2004-06-28 |
2008-11-13 |
Wender Paul A |
Laulimalide Analogues as Therapeutic Agents
|
US20060004185A1
(en)
*
|
2004-07-01 |
2006-01-05 |
Leese Richard A |
Peptide antibiotics and peptide intermediates for their prepartion
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
JP5060293B2
(ja)
|
2004-08-03 |
2012-10-31 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
神経機能におけるtaj
|
CA2574881C
(en)
|
2004-08-04 |
2013-01-08 |
Amgen Inc. |
Antibodies to dkk-1
|
CA2575988C
(en)
*
|
2004-08-04 |
2014-02-18 |
Brookwood Pharmaceuticals, Inc. |
Methods for manufacturing delivery devices and devices thereof
|
AU2005271242B9
(en)
|
2004-08-12 |
2012-04-12 |
Foresee Pharmaceuticals Co., Ltd. |
Pharmaceutical compositions for controlled release delivery of biologically active compounds
|
JP5070052B2
(ja)
|
2004-08-17 |
2012-11-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
Pde5阻害剤組成物及び心臓疾患を治療する方法
|
WO2006029406A2
(en)
*
|
2004-09-09 |
2006-03-16 |
Stryker Corporation |
Methods for treating bone tumors using bone morphogenic proteins
|
ES2378671T3
(es)
*
|
2004-09-17 |
2012-04-16 |
Durect Corporation |
Composición anestésica local prolongada que contiene SAIB
|
CA2583061C
(en)
|
2004-10-06 |
2015-02-17 |
Kwang Guan Tay |
Antibody production method
|
FR2876379B1
(fr)
*
|
2004-10-08 |
2008-09-05 |
Isochem Sa |
Procede de polymerisation des o-carboxy anhydrides
|
US8034345B2
(en)
|
2004-10-15 |
2011-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-PCI antibody for regulating liver regeneration/repair
|
JP2008520684A
(ja)
|
2004-11-17 |
2008-06-19 |
アブジェニックス・インコーポレーテッド |
Il−13に対する完全ヒトモノクローナル抗体
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
GB0425854D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Astrazeneca Ab |
Therapeutic treatment
|
EP1838737B1
(en)
|
2004-12-20 |
2011-04-06 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
US7973140B2
(en)
|
2004-12-21 |
2011-07-05 |
Medimmune Limited |
Antibodies directed to angiopoietin-2 and uses thereof
|
CA2927595C
(en)
|
2004-12-22 |
2023-01-31 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
CN103690936A
(zh)
|
2004-12-22 |
2014-04-02 |
Ambrx公司 |
经修饰的人类生长激素
|
EP1835885A1
(en)
*
|
2004-12-23 |
2007-09-26 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
|
EP2351577A1
(en)
*
|
2004-12-29 |
2011-08-03 |
Mannkind Corporation |
Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
|
AU2006208286A1
(en)
|
2005-01-26 |
2006-08-03 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
CA2604052C
(en)
*
|
2005-04-06 |
2014-07-08 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cns-related conditions
|
EP1876236B9
(en)
|
2005-04-08 |
2015-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
JP2008538501A
(ja)
*
|
2005-04-20 |
2008-10-30 |
オークランド ユニサービシーズ リミティド |
ベシキュリン
|
WO2006116565A2
(en)
*
|
2005-04-25 |
2006-11-02 |
Amgen Inc. |
Biodegradable peptide sustained release compositions containing porogens
|
EP1716847B1
(en)
|
2005-04-28 |
2008-01-02 |
Nipro Corporation |
Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer
|
CA2605508A1
(en)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
CA2960117C
(en)
|
2005-05-17 |
2018-01-30 |
Sarcode Bioscience Inc. |
Lfa-1 antagonists for the treatment of eye disorders
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
JP5224580B2
(ja)
|
2005-06-10 |
2013-07-03 |
中外製薬株式会社 |
sc(Fv)2部位特異的変異体
|
WO2006132363A1
(ja)
|
2005-06-10 |
2006-12-14 |
Chugai Seiyaku Kabushiki Kaisha |
メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
|
US20080311078A1
(en)
|
2005-06-14 |
2008-12-18 |
Gokarn Yatin R |
Self-Buffering Protein Formulations
|
SI2314623T1
(sl)
|
2005-06-21 |
2012-11-30 |
Xoma Technology Ltd |
IL beta vezavna protitelesa in njihovi fragmenti
|
RS53058B
(en)
|
2005-07-08 |
2014-04-30 |
Biogen Idec Ma Inc. |
SP35 ANTIBODIES AND THEIR APPLICATIONS
|
EP1915398B1
(en)
|
2005-07-18 |
2016-04-20 |
Amgen Inc. |
Human anti-b7rp1 neutralizing antibodies
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
CN101267779A
(zh)
|
2005-07-27 |
2008-09-17 |
福罗里达大学研究基金会有限公司 |
使用热休克治疗眼睛疾病
|
EP2497781A1
(en)
|
2005-09-08 |
2012-09-12 |
Trustees Of Tufts College |
Stabilized GLP-1 analogs
|
JP2009509943A
(ja)
|
2005-09-27 |
2009-03-12 |
ステム セル セラピューティクス コーポレイション |
プロラクチンにより制御される乏突起膠細胞前駆体細胞の増殖
|
PL1937262T3
(pl)
|
2005-09-29 |
2019-10-31 |
Ipsen Pharma |
Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
|
US8852638B2
(en)
|
2005-09-30 |
2014-10-07 |
Durect Corporation |
Sustained release small molecule drug formulation
|
AU2006344395B2
(en)
|
2005-10-13 |
2013-05-02 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive diseases
|
AU2006300234B2
(en)
|
2005-10-14 |
2013-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for suppressing damage to transplanted islets after islet transplantation
|
CN101330930B
(zh)
|
2005-10-21 |
2011-11-23 |
中外制药株式会社 |
心脏病治疗剂
|
EP2510934A1
(en)
|
2005-11-04 |
2012-10-17 |
Biogen Idec MA Inc. |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
US7942867B2
(en)
*
|
2005-11-09 |
2011-05-17 |
The Invention Science Fund I, Llc |
Remotely controlled substance delivery device
|
EP2548583A3
(en)
|
2005-11-10 |
2013-02-27 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
JP5398987B2
(ja)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AU2006315347A1
(en)
|
2005-11-16 |
2007-05-24 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
TW200803894A
(en)
|
2005-11-25 |
2008-01-16 |
Univ Keio |
Prostate cancer therapeutic agents
|
NZ569086A
(en)
|
2005-12-01 |
2011-07-29 |
Trinity College Dublin |
Compositions comprising a Toll-like receptor (TLR) agonist and an immune modulator for treating Th1-mediated conditions, such as cancer and infectious diseases
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
EP1965827B1
(en)
|
2005-12-02 |
2015-02-25 |
Biogen Idec MA Inc. |
Treatment of conditions involving demyelination
|
EP1962872B1
(en)
|
2005-12-05 |
2014-05-28 |
The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin |
Compositions and methods for modulating an immune response
|
US8158588B2
(en)
|
2005-12-05 |
2012-04-17 |
Simon Delagrave |
Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
|
US7939637B2
(en)
|
2005-12-13 |
2011-05-10 |
Medimmune Limited |
Insulin-like growth factor antibodies and uses thereof
|
EP1969003B8
(en)
|
2005-12-14 |
2010-11-10 |
Hermo Pharma Ltd. |
Uses of a NEUROTROPHIC FACTOR PROTEIN
|
CA2633211A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
EP3363455A1
(en)
|
2005-12-30 |
2018-08-22 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
US20070154546A1
(en)
*
|
2005-12-30 |
2007-07-05 |
Zhang Jack Y |
Sustained release pharmaceutical compositions
|
US20100167341A1
(en)
|
2006-01-17 |
2010-07-01 |
Dnavec Corporation |
Novel protein expression system
|
ES2397712T3
(es)
|
2006-01-18 |
2013-03-08 |
Qps, Llc |
Composiciones farmacéuticas con estabilidad reforzada
|
US8771686B2
(en)
|
2006-01-27 |
2014-07-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
|
WO2007089601A2
(en)
|
2006-01-27 |
2007-08-09 |
Biogen Idec Ma Inc. |
Nogo receptor antagonists
|
CU23388B6
(es)
|
2006-01-31 |
2009-07-16 |
Ct Ingenieria Genetica Biotech |
Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
ES2381631T3
(es)
*
|
2006-02-02 |
2012-05-30 |
Synageva Biopharma Corp. |
Péptidos inhibidores de la fusión del VIH con propiedades biológicas mejoradas
|
EP1987142A4
(en)
|
2006-02-02 |
2009-07-15 |
Verenium Corp |
ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS
|
AU2007229301B2
(en)
*
|
2006-03-17 |
2013-08-01 |
Stem Cell Therapeutics Corp. |
Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
|
EP1837014A1
(en)
*
|
2006-03-21 |
2007-09-26 |
Hexal Ag |
Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
|
WO2007116962A1
(ja)
|
2006-04-07 |
2007-10-18 |
Osaka University |
筋再生促進剤
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
EP2548579B1
(en)
|
2006-05-17 |
2015-09-02 |
The Ludwig Institute for Cancer Research |
Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
|
US20090298761A1
(en)
|
2006-05-17 |
2009-12-03 |
Donald Engelman |
Methods of treating cartilage defects using a soluble morphogenic protein complex
|
US7403325B2
(en)
*
|
2006-05-19 |
2008-07-22 |
Xerox Corporation |
Electrophoretic display device
|
WO2007137245A2
(en)
|
2006-05-22 |
2007-11-29 |
Columbia University |
Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
EP2049570B1
(en)
|
2006-06-01 |
2016-08-10 |
President and Fellows of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
CA2654623C
(en)
|
2006-06-08 |
2016-07-26 |
Chugai Seiyaku Kabushiki Kaisha |
An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
US20080015546A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Casas Jesus W |
Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
|
US20100150927A1
(en)
|
2006-07-13 |
2010-06-17 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death inducer
|
EP2574625B1
(en)
|
2006-07-21 |
2015-02-25 |
HuBit genomix, Inc. |
Remedy for renal disease
|
AU2007279205B2
(en)
|
2006-07-28 |
2013-09-26 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
JP5256199B2
(ja)
|
2006-08-07 |
2013-08-07 |
テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド |
アルブミン−インスリン融合タンパク質
|
CA2663083A1
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
SG154441A1
(en)
|
2006-10-20 |
2009-08-28 |
Biogen Idec Inc |
Treatment of demyelinating disorders
|
US8338376B2
(en)
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
EP2117521B1
(en)
|
2006-11-03 |
2012-06-27 |
Durect Corporation |
Transdermal delivery systems comprising bupivacaine
|
MX2009004757A
(es)
|
2006-11-14 |
2009-05-21 |
Genentech Inc |
Moduladores de regeneracion neuronal.
|
WO2008073300A2
(en)
|
2006-12-08 |
2008-06-19 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
TWI481424B
(zh)
|
2006-12-18 |
2015-04-21 |
Takeda Pharmaceutical |
緩釋性組成物及其製法
|
US7695718B2
(en)
|
2006-12-20 |
2010-04-13 |
Xoma Technology Ltd. |
Methods for the treatment of IL-1β related diseases
|
HUE036793T2
(hu)
|
2007-01-09 |
2018-07-30 |
Biogen Ma Inc |
SP35 antitestek és alkalmazásuk
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
MX2009007830A
(es)
|
2007-01-23 |
2009-10-07 |
Univ Shinshu |
Inhibidor de rechazo cronico.
|
NZ578816A
(en)
|
2007-02-02 |
2012-06-29 |
Biogen Idec Inc |
Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
WO2008121563A2
(en)
|
2007-03-30 |
2008-10-09 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
JP2010523564A
(ja)
*
|
2007-04-03 |
2010-07-15 |
トリメリス,インコーポレーテッド |
抗ウイルス性ペプチド治療薬の送達のための新規製剤
|
RU2473331C2
(ru)
|
2007-04-13 |
2013-01-27 |
Юниверсити Оф Норс Техас Хэлс Саенс Сентер Эт Форт Ворс |
Состав активированных наночастиц plga, загруженных активным средством, для целенаправленной нанотерапии рака
|
US20100290982A1
(en)
*
|
2007-04-13 |
2010-11-18 |
University Of North Texas Health Science Center At Fort Worth |
Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
|
EP2153736B1
(en)
|
2007-05-11 |
2017-04-19 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor antagonist from marine sources
|
CN101677952B
(zh)
|
2007-05-18 |
2012-12-05 |
杜雷科特公司 |
改进的贮库制剂
|
NZ581862A
(en)
|
2007-05-25 |
2012-06-29 |
Tolmar Therapeutics Inc |
Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient
|
DK2170930T3
(da)
|
2007-06-04 |
2012-11-05 |
Synergy Pharmaceuticals Inc |
Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
GB0710976D0
(en)
|
2007-06-07 |
2007-07-18 |
Bioalvo |
Am Screening method
|
EP3461500A1
(en)
|
2007-06-14 |
2019-04-03 |
Biogen MA Inc. |
Natalizumab antibody formulations
|
EP3666284A1
(en)
|
2007-06-22 |
2020-06-17 |
Children's Medical Center, Corp. |
Methods and uses thereof of a fragment of saposin a
|
EP2164870B1
(en)
|
2007-06-27 |
2015-12-09 |
National University of Singapore |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
DE102007036101A1
(de)
*
|
2007-08-01 |
2009-02-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue glycolidreiche Copolymere
|
TW200916113A
(en)
|
2007-08-08 |
2009-04-16 |
Sod Conseils Rech Applic |
Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
|
NO2188313T3
(hu)
|
2007-08-21 |
2018-03-31 |
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP2615113A3
(en)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
JP2010540528A
(ja)
*
|
2007-09-25 |
2010-12-24 |
トリメリス,インコーポレーテッド |
治療的抗ウイルス性ペプチドの新規合成方法
|
EP2207809B1
(en)
|
2007-09-26 |
2013-07-03 |
U3 Pharma GmbH |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
JP2010540618A
(ja)
*
|
2007-10-02 |
2010-12-24 |
アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド |
幼児の成長および発達を増大するための内在性カンナビノイド
|
AU2008308163B2
(en)
|
2007-10-02 |
2013-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
|
US20090123508A1
(en)
*
|
2007-10-04 |
2009-05-14 |
Boston Scientific Scimed, Inc. |
Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
|
WO2009054914A1
(en)
|
2007-10-19 |
2009-04-30 |
Sarcode Corporation |
Compositions and methods for treatment of diabetic retinopathy
|
EP2219620B1
(en)
*
|
2007-11-13 |
2017-07-19 |
Surmodics, Inc. |
Viscous terpolymers as drug delivery platform
|
KR101478995B1
(ko)
|
2007-11-16 |
2015-01-12 |
더 락커펠러 유니버시티 |
원섬유 형태의 베타아밀로이드 단백질에 대해 특이적인 항체
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
ES2834741T3
(es)
|
2007-12-05 |
2021-06-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-NR10 y uso del mismo
|
MX2010006097A
(es)
|
2007-12-05 |
2010-08-04 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para tratar el prurito.
|
CA2706931C
(en)
*
|
2007-12-06 |
2015-05-12 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
MX2010006823A
(es)
|
2007-12-20 |
2010-09-30 |
Xoma Technology Ltd |
Metodos para el tratamiento de la gota.
|
US20090181068A1
(en)
|
2008-01-14 |
2009-07-16 |
Dunn Richard L |
Low Viscosity Liquid Polymeric Delivery System
|
BRPI0907473A2
(pt)
*
|
2008-02-04 |
2019-09-24 |
Univ Columbia |
métodos, sistemas e dispositivos de separação de fluidos
|
CN103694337B
(zh)
|
2008-02-08 |
2016-03-02 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
AU2009216216B2
(en)
*
|
2008-02-22 |
2013-11-07 |
Toray Industries, Inc. |
Microparticles and pharmaceutical compositions thereof
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
TWI528973B
(zh)
|
2008-06-05 |
2016-04-11 |
Chugai Pharmaceutical Co Ltd |
Nerve infiltration inhibitor
|
DK2684873T3
(en)
|
2008-06-09 |
2019-04-01 |
Univ Muenchen Ludwig Maximilians |
PHARMACEUTICALS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES CONNECTED WITH PROTEIN AGGREGATION AND / OR NEURODEGENERATIVE DISEASE
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
EP2982695B1
(en)
|
2008-07-09 |
2019-04-03 |
Biogen MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
EP3225248B1
(en)
|
2008-07-23 |
2023-06-07 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
US8415159B2
(en)
|
2008-07-30 |
2013-04-09 |
Mesynthes Ltd. |
Tissue scaffolds derived from forestomach extracellular matrix
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8198062B2
(en)
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
BRPI0913476A2
(pt)
|
2008-09-10 |
2015-12-01 |
Genentech Inc |
"usos de um antagonista tspan12 e usos de um antagonista de norrin"
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
CA2738033C
(en)
|
2008-09-26 |
2019-11-26 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
CA2737026C
(en)
|
2008-09-26 |
2019-12-24 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
JP2012504969A
(ja)
|
2008-10-10 |
2012-03-01 |
アナフォア インコーポレイテッド |
Trail−r1及びtrail−r2に結合するポリペプチド
|
SG195542A1
(en)
|
2008-10-10 |
2013-12-30 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
JP5851838B2
(ja)
|
2008-10-22 |
2016-02-03 |
ジェネンテック, インコーポレイテッド |
軸索変性の調節
|
EP4104821A1
(en)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
CA2744120A1
(en)
|
2008-11-17 |
2010-05-20 |
The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, |
A vaccinia virus protein a46 peptide and use thereof
|
NZ627111A
(en)
|
2008-11-26 |
2015-10-30 |
Amgen Inc |
Variants of activin iib receptor polypeptides and uses thereof
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
WO2010072684A1
(en)
|
2008-12-22 |
2010-07-01 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
NZ593892A
(en)
|
2008-12-23 |
2013-11-29 |
Biosource Pharm Inc |
Antibiotic compositions for the treatment of gram negative infections
|
US20100158978A1
(en)
*
|
2008-12-23 |
2010-06-24 |
Peter Markland |
Bioactive spray coating compositions and methods of making and uses thereof
|
US9415197B2
(en)
|
2008-12-23 |
2016-08-16 |
Surmodics, Inc. |
Implantable suction cup composites and implants comprising same
|
US8974808B2
(en)
*
|
2008-12-23 |
2015-03-10 |
Surmodics, Inc. |
Elastic implantable composites and implants comprising same
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
US20100168807A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Burton Kevin W |
Bioactive terpolymer compositions and methods of making and using same
|
US8951546B2
(en)
|
2008-12-23 |
2015-02-10 |
Surmodics Pharmaceuticals, Inc. |
Flexible implantable composites and implants comprising same
|
US20110294733A1
(en)
|
2009-01-20 |
2011-12-01 |
Hanall Biopharma Co., Ltd. |
Modified human thrombopoietin polypeptide fragment and manufacturing method thereof
|
WO2010085609A2
(en)
*
|
2009-01-23 |
2010-07-29 |
Surmodics Pharmaceuticals, Inc. |
Controlled release systems from polymer blends
|
EP2389413A1
(en)
*
|
2009-01-23 |
2011-11-30 |
Surmodics Pharmaceuticals, Inc. |
Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
|
US20110014190A1
(en)
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
AU2010212851B2
(en)
|
2009-02-13 |
2012-12-13 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
TW201031436A
(en)
*
|
2009-02-16 |
2010-09-01 |
Univ Nat Taiwan |
Pharmaceutical composition for inhalation delivery and fabrication method thereof
|
US20120114757A1
(en)
|
2009-02-18 |
2012-05-10 |
Bayer Pharma Aktiengesellschaft |
Particles comprising drospirenone encapsulated in a polymer
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
TWI560197B
(en)
|
2009-05-05 |
2016-12-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
CA2760674A1
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
WO2010144797A2
(en)
|
2009-06-12 |
2010-12-16 |
Vaccine Technologies, Incorporated |
Influenza vaccines with enhanced immunogenicity and uses thereof
|
IN2012DN00352A
(hu)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
WO2010148142A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
WO2011010131A1
(en)
|
2009-07-21 |
2011-01-27 |
Astrazeneca Ab |
Compositions comprising an oxoisoquinoline methylbenzamide and a polymer
|
WO2011010132A1
(en)
|
2009-07-21 |
2011-01-27 |
Astrazeneca Ab |
Sustained-release composition comprising compound 600
|
JP5752038B2
(ja)
|
2009-07-31 |
2015-07-22 |
愼 前田 |
癌の転移抑制剤
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
EP2308478A1
(en)
|
2009-10-06 |
2011-04-13 |
Abbott GmbH & Co. KG |
Delivery system for sustained release of a calcium-channel blocking agent
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
EP2488186B1
(en)
|
2009-10-16 |
2017-05-24 |
National University of Singapore |
Anti-neoplastic uses of artemin antagonists
|
CN102574907B
(zh)
|
2009-10-19 |
2015-10-21 |
韩诺生物制药株式会社 |
修饰的人肿瘤坏死因子受体i多肽或其片段以及制备它们的方法
|
US8378105B2
(en)
|
2009-10-21 |
2013-02-19 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
AU2010310589A1
(en)
|
2009-10-22 |
2012-05-10 |
Genentech, Inc. |
Modulation of axon degeneration
|
WO2011056650A2
(en)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
CN113528485A
(zh)
|
2009-11-02 |
2021-10-22 |
华盛顿大学 |
治疗性核酸酶组合物和方法
|
CA2780763A1
(en)
|
2009-11-13 |
2011-05-19 |
Puget Sound Blood Center |
Factor viii b cell epitope variants having reduced immunogenicity
|
CN104961829B
(zh)
|
2009-11-24 |
2018-08-21 |
米迪缪尼有限公司 |
针对b7-h1的靶向结合剂
|
WO2011066260A2
(en)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
MX2012006320A
(es)
|
2009-12-02 |
2013-01-18 |
Adamas Pharmaceuticals Inc |
Composiciones de amantadina y metodos para su uso.
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
EP3366695B1
(en)
|
2009-12-17 |
2021-07-07 |
Children's Medical Center Corporation |
Saposin-a derived peptides and uses thereof
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
MX349301B
(es)
|
2009-12-21 |
2017-07-21 |
Ambrx Inc |
Polipéptidos de somatotropina bovina modificados y sus usos.
|
US8936804B2
(en)
|
2010-01-15 |
2015-01-20 |
Rutgers, The State University Of New Jersey |
Use of vanadium compounds to accelerate bone healing
|
US20130053438A1
(en)
|
2010-01-19 |
2013-02-28 |
Universitat Innsbruck |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
EP2528938A4
(en)
|
2010-01-27 |
2013-10-23 |
Childrens Medical Center |
PROANGIOGENIC FRAGMENTS OF PROMININ 1 AND USES THEREOF
|
EP2528943A1
(en)
|
2010-01-28 |
2012-12-05 |
Novo Nordisk Health Care AG |
Factor vii fusion polypeptides
|
WO2011099007A1
(en)
|
2010-02-10 |
2011-08-18 |
Nayacure Therapeutics Ltd. |
Pharmaceutical compositions and methods for the treatment and prevention of cancer
|
GB201003559D0
(en)
|
2010-03-03 |
2010-04-21 |
Proteo Biotech Ag |
Novel use of elafin
|
US20130039947A1
(en)
|
2010-03-12 |
2013-02-14 |
Children's Medical Center Corporation |
Novel immunogens and methods for discovery and screening thereof
|
EP2554552B1
(en)
|
2010-03-26 |
2015-05-13 |
The University of Tokushima |
Novel anti-cd98 antibody and use thereof
|
AU2011239689A1
(en)
|
2010-04-15 |
2012-11-08 |
Amgen Inc. |
Human FGF receptor and beta-Klotho binding proteins
|
WO2011131626A1
(en)
|
2010-04-19 |
2011-10-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
MX339805B
(es)
|
2010-04-22 |
2016-06-10 |
Intra-Cellular Therapies Inc |
Compuestos organicos.
|
GB201007531D0
(en)
|
2010-05-05 |
2010-06-23 |
Imp Innovations Ltd |
Composition
|
EP3181692A1
(en)
|
2010-05-07 |
2017-06-21 |
Centre National De La Recherche Scientifique |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
WO2011146938A1
(en)
|
2010-05-21 |
2011-11-24 |
NanoOncology, Inc. |
Reagents and methods for treating cancer
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
US9539322B2
(en)
|
2010-05-28 |
2017-01-10 |
National University Corporation Hokkaido University |
Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
|
US20130115237A1
(en)
|
2010-06-09 |
2013-05-09 |
Vaccine Technologies, Incorporated |
Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
|
BR112012032189B1
(pt)
|
2010-06-16 |
2020-11-03 |
Endorecherche, Inc |
usos de um agonista ou antagonista de lhrh em associação com um modulador de receptor de estrogênio seletivo e com um precursor de esteróide sexual para a preparação de uma medicamento para o tratamento ou prevenção de doenças relacionadas com estrogênio e kits
|
CN103038253A
(zh)
|
2010-06-18 |
2013-04-10 |
西伯尔科学有限公司 |
作为用来稳定生物屏障的活性剂的肽
|
US8415307B1
(en)
|
2010-06-23 |
2013-04-09 |
Biosource Pharm, Inc. |
Antibiotic compositions for the treatment of gram negative infections
|
WO2011161531A1
(en)
|
2010-06-24 |
2011-12-29 |
Torrent Pharmaceuticals Limited |
Pharmaceutical composition containing goserelin for in-situ implant
|
US9211175B2
(en)
|
2010-07-08 |
2015-12-15 |
Covidien Lp |
Self-detachable medical devices
|
FR2962646B1
(fr)
|
2010-07-16 |
2012-06-22 |
Sofradim Production |
Prothese avec element radio-opaque
|
JP2013536175A
(ja)
|
2010-07-16 |
2013-09-19 |
アブリンクス エン.ヴェー. |
修飾された単一ドメイン抗原結合分子及びその使用
|
UY33517A
(es)
|
2010-07-19 |
2012-02-29 |
Astrazeneca Ab |
Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
|
DK2605789T3
(da)
|
2010-08-17 |
2019-09-16 |
Ambrx Inc |
Modificerede relaxinpolypeptider og anvendelser deraf
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
WO2012030819A1
(en)
|
2010-08-30 |
2012-03-08 |
Surmodics Pharmaceuticals, Inc. |
Terpolymers as pressure-sensitive adhesives
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
EP2623592B1
(en)
|
2010-09-28 |
2019-05-15 |
NB Health Laboratory Co. Ltd. |
Anti-human ccr7 antibodies, hybridoma, medicinal composition, and antibody-immobilized carrier
|
US9572907B2
(en)
|
2010-10-01 |
2017-02-21 |
Covidien Lp |
Implantable polymeric films
|
CA2813304A1
(en)
|
2010-10-01 |
2012-04-05 |
Biogen Idec Ma Inc. |
Interferon-beta for use as monotherapy or in combination with other cancer therapies
|
US8920867B2
(en)
|
2010-10-19 |
2014-12-30 |
Covidien Lp |
Methods of forming self-supporting films for delivery of therapeutic agents
|
US9861590B2
(en)
|
2010-10-19 |
2018-01-09 |
Covidien Lp |
Self-supporting films for delivery of therapeutic agents
|
US8632839B2
(en)
|
2010-10-19 |
2014-01-21 |
Covidien Lp |
Methods of forming self-supporting films for delivery of therapeutic agents
|
WO2012061120A1
(en)
|
2010-10-25 |
2012-05-10 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
AU2011323508B2
(en)
|
2010-11-01 |
2017-04-27 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
MY166429A
(en)
|
2010-11-17 |
2018-06-26 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
GB201019467D0
(en)
|
2010-11-17 |
2010-12-29 |
Biotecnol Sa |
Therapeutic agent
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
US20130302346A1
(en)
|
2010-11-24 |
2013-11-14 |
Lexicon Pharmaceuticals, Inc. |
Antibodies that bind notum pectinacetylesterase
|
EP2647707B1
(en)
|
2010-11-30 |
2018-09-12 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
KR101185310B1
(ko)
|
2010-12-23 |
2012-09-21 |
한올바이오파마주식회사 |
변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US9144634B2
(en)
|
2011-01-14 |
2015-09-29 |
Covidien Lp |
Medical device with intrapore films
|
WO2012102679A1
(en)
|
2011-01-24 |
2012-08-02 |
National University Of Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
DK2667715T3
(en)
|
2011-01-27 |
2017-10-23 |
Neuren Pharmaceuticals Ltd |
TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID
|
EA201391248A1
(ru)
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
EP2683368A1
(en)
|
2011-03-10 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
Treatment of disorders with altered vascular barrier function
|
WO2012138774A2
(en)
|
2011-04-04 |
2012-10-11 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
JP5977814B2
(ja)
|
2011-04-08 |
2016-08-24 |
アムジエン・インコーポレーテツド |
増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法
|
BR112013027235B1
(pt)
|
2011-04-25 |
2021-11-16 |
Shan Dong Luye Pharmaceutical Co., Ltd |
Composição farmacêutica, seu uso, e formulação de microsferas para injeção de liberação sustentada
|
IL300276B1
(en)
|
2011-04-29 |
2024-07-01 |
Univ Washington |
Therapeutic nuclease preparations and methods
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
WO2012151343A1
(en)
|
2011-05-04 |
2012-11-08 |
Balance Therapeutics, Inc. |
Pentylenetetrazole derivatives
|
MX2013013044A
(es)
|
2011-05-10 |
2014-02-20 |
Amgen Inc |
METODO PARA IDENTIFICAR COMPUESTOS QUE ESPECIFICAMENTE MODULAN LA INTERACCION DE FGFR1 Y ß-KLOTHO.
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
EP2706991B1
(en)
|
2011-05-11 |
2021-03-24 |
Children's Medical Center Corporation |
Multiple antigen presenting immunogenic composition, and methods and uses thereof
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
AU2012271728B2
(en)
|
2011-06-14 |
2016-10-20 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US20140227265A1
(en)
|
2011-06-17 |
2014-08-14 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
FR2977790B1
(fr)
|
2011-07-13 |
2013-07-19 |
Sofradim Production |
Prothese pour hernie ombilicale
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
US8579924B2
(en)
|
2011-07-26 |
2013-11-12 |
Covidien Lp |
Implantable devices including a mesh and a pivotable film
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
US9328386B2
(en)
|
2011-08-16 |
2016-05-03 |
Evotec (München) Gmbh |
Markers for susceptibility to an inhibitor of an Src-family kinase
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP2744828A4
(en)
|
2011-08-16 |
2014-12-31 |
Univ Emory |
JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
|
EP2744508B1
(en)
|
2011-08-19 |
2017-11-08 |
Children's Medical Center Corporation |
Vegf-binding protein for blockade of angiogenesis
|
US9782957B2
(en)
|
2011-08-24 |
2017-10-10 |
Covidien Lp |
Medical device films
|
US20140213512A1
(en)
|
2011-08-31 |
2014-07-31 |
Amgen Inc. |
Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
UA118332C2
(uk)
|
2011-09-22 |
2019-01-10 |
Емджен Інк. |
Білок, що зв'язує антиген cd27l
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
US9006400B2
(en)
|
2011-09-26 |
2015-04-14 |
Novartis Ag |
Fibroblast growth factor-21-Fc fusion proteins
|
KR102492584B1
(ko)
|
2011-09-30 |
2023-01-27 |
추가이 세이야쿠 가부시키가이샤 |
표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
|
DE102011114864A1
(de)
|
2011-10-05 |
2013-04-11 |
Acino Ag |
Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
US20130172265A1
(en)
|
2011-10-14 |
2013-07-04 |
The Board Of Trustees Of The University Of Illinois |
Methods and Compositions for Inhibiting Tumor Cell Proliferation
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
AU2012325341B2
(en)
|
2011-10-19 |
2017-01-05 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US9005308B2
(en)
|
2011-10-25 |
2015-04-14 |
Covidien Lp |
Implantable film/mesh composite for passage of tissue therebetween
|
US9179994B2
(en)
|
2011-10-25 |
2015-11-10 |
Covidien Lp |
Implantable film/mesh composite
|
US8932621B2
(en)
|
2011-10-25 |
2015-01-13 |
Covidien Lp |
Implantable film/mesh composite
|
AP2014007638A0
(en)
|
2011-11-16 |
2014-05-31 |
Amgen Inc |
Methods of treating epidermal growth factor deletion mutant VIII related disorders
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
EP2785346A4
(en)
|
2011-11-30 |
2015-04-29 |
Bikam Pharmaceuticals Inc |
OPSINBINDING LIGANDS, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
|
AU2012346537A1
(en)
|
2011-12-01 |
2014-07-17 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CN104220460A
(zh)
|
2011-12-08 |
2014-12-17 |
安姆根有限公司 |
激动人lcat抗原结合蛋白和它们在疗法中的用途
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
MX358358B
(es)
|
2011-12-19 |
2018-08-15 |
Amgen Inc |
Polipeptidos de receptores de activina variantes y sus usos.
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
US10736935B2
(en)
|
2011-12-22 |
2020-08-11 |
Children's Medical Center Corporation |
Saposin-A derived peptides and uses thereof
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
JP2015504674A
(ja)
|
2012-01-11 |
2015-02-16 |
アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーArizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
神経疾患タンパク質の二重特異性抗体フラグメントおよび使用方法
|
BR112014018575A2
(pt)
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
CN104271772A
(zh)
|
2012-03-29 |
2015-01-07 |
科罗拉多州立大学董事会,公司实体 |
点击核酸
|
US10206769B2
(en)
|
2012-03-30 |
2019-02-19 |
Covidien Lp |
Implantable devices including a film providing folding characteristics
|
US8753643B1
(en)
|
2012-04-11 |
2014-06-17 |
Life-Science Innovations, Llc |
Spray dried compositions and methods of use
|
US9428506B2
(en)
|
2012-04-14 |
2016-08-30 |
Intra-Cellular Therapies, Inc. |
Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
|
US20150118237A1
(en)
|
2012-04-23 |
2015-04-30 |
Genefrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
AU2013262934B2
(en)
|
2012-05-14 |
2018-02-01 |
Biogen Ma Inc. |
LINGO-2 antagonists for treatment of conditions involving motor neurons
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
FR2992662B1
(fr)
|
2012-06-28 |
2014-08-08 |
Sofradim Production |
Tricot avec picots
|
FR2992547B1
(fr)
|
2012-06-29 |
2015-04-24 |
Sofradim Production |
Prothese pour hernie
|
WO2014006063A2
(en)
|
2012-07-02 |
2014-01-09 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
CA2879982C
(en)
|
2012-07-25 |
2020-09-01 |
Sarcode Bioscience Inc. |
Lfa-1 inhibitor and polymorph thereof
|
DE102013011399A1
(de)
|
2012-07-31 |
2014-02-06 |
Amw Gmbh |
Implantat mit Risperidon
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
EP2887942A4
(en)
|
2012-08-21 |
2016-08-31 |
Genesys Res Inst |
COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF ANTHRACYCLIN-INDUCED CARDIOTOXICITY
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
HUE042262T2
(hu)
|
2012-10-17 |
2019-06-28 |
Vascular Biogenics Ltd |
FAS-kimérát kifejezõ adenovírus és alkalmazása rákkezelési módszerekben
|
CA2890862C
(en)
|
2012-11-09 |
2021-10-12 |
Genefrontier Corporation |
Anti-adam28 antibody for treating cancer
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-l1阻害剤併用療法を必要とする患者の同定
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
EP2934588A4
(en)
|
2012-12-20 |
2016-09-28 |
Medimmune Llc |
LIQUID ANTIBODY FORMULATION HAVING ENHANCED AGGREGATION PROPERTIES
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
CN105431455A
(zh)
|
2013-02-01 |
2016-03-23 |
圣塔玛丽亚生物疗法公司 |
抗激活素a化合物对受试者的施用
|
AU2014214844B2
(en)
|
2013-02-07 |
2017-12-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
EP2958577A2
(en)
|
2013-02-25 |
2015-12-30 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase receptor agonists for use in colonic cleansing
|
BR112015022023B1
(pt)
|
2013-03-11 |
2022-12-06 |
Durect Corporation |
Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
|
US20140308352A1
(en)
|
2013-03-11 |
2014-10-16 |
Zogenix Inc. |
Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
ES2770976T3
(es)
|
2013-03-15 |
2020-07-06 |
Amgen Inc |
Anticuerpos PAC1 humanos
|
AU2014236867A1
(en)
|
2013-03-15 |
2015-09-24 |
Amgen Inc. |
Methods and compositions relating to anti-CCR7 antigen binding proteins
|
AU2014233453A1
(en)
|
2013-03-15 |
2015-10-01 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
EP2968320B1
(en)
|
2013-03-15 |
2020-11-11 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
US9474792B2
(en)
|
2013-03-15 |
2016-10-25 |
Amgen Inc. |
Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
UY35484A
(es)
|
2013-03-15 |
2014-10-31 |
Amgen Res Munich Gmbh |
Molécula de unión de cadena simple que comprenden ABP de extremo N
|
CN104107434B
(zh)
*
|
2013-04-18 |
2017-02-01 |
山东绿叶制药有限公司 |
戈舍瑞林缓释微球药物组合物
|
EP3461909A1
(en)
|
2013-05-21 |
2019-04-03 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
EP3610905B1
(en)
|
2013-05-22 |
2021-03-31 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for treating heart failure
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
NZ713636A
(en)
|
2013-05-30 |
2022-07-01 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
WO2014197938A1
(en)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Combination therapy
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
WO2014209384A1
(en)
|
2013-06-28 |
2014-12-31 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolema
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN105814074B
(zh)
|
2013-07-18 |
2020-04-21 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
EP3027642B1
(en)
|
2013-07-31 |
2020-08-19 |
Amgen Inc. |
Growth differentiation factor 15 (gdf-15) constructs
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
EP3712166A1
(en)
|
2013-09-05 |
2020-09-23 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
JP6863742B2
(ja)
|
2013-09-11 |
2021-04-21 |
ジ・アドミニストレーターズ・オブ・ザ・チューレーン・エデュケーショナル・ファンド |
新規アントラニルアミドとその使用
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
KR102302634B1
(ko)
|
2013-09-13 |
2021-09-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제 및 이의 조성물
|
EP2808338B1
(en)
|
2013-09-16 |
2016-03-30 |
CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Mutant calreticulin for the diagnosis of myeloid malignancies
|
EP3047857A4
(en)
|
2013-09-20 |
2017-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
GB201316738D0
(en)
|
2013-09-20 |
2013-11-06 |
Rainbow Medical Engineering Ltd |
Implantable Medical Devices
|
EP3521431A1
(en)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
KR20160058960A
(ko)
|
2013-10-04 |
2016-05-25 |
압토스 바이오사이언시스 인코포레이티드 |
암을 치료하기 위한 조성물과 방법
|
JP6661531B2
(ja)
|
2013-10-10 |
2020-03-11 |
シナジー ファーマシューティカルズ インコーポレイテッド |
オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
|
KR102357968B1
(ko)
|
2013-10-15 |
2022-02-03 |
더 스크립스 리서치 인스티튜트 |
키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
WO2015056808A1
(en)
|
2013-10-15 |
2015-04-23 |
Genefrontier Corporation |
Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
US20160235810A1
(en)
|
2013-10-18 |
2016-08-18 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
EP3063168B1
(en)
|
2013-10-30 |
2019-03-06 |
University of Western Australia |
Neuroprotective peptides
|
ES2759252T3
(es)
|
2013-10-31 |
2020-05-08 |
Resolve Therapeutics Llc |
Fusiones y métodos terapéuticos de nucleasa-albúmina
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
IL305990A
(en)
|
2013-12-03 |
2023-11-01 |
Intra Cellular Therapies Inc |
Compressed gamma-carboline heterocyclic compounds are modified for use in the treatment of type I and/or type II bipolar disorders
|
EP3082797A4
(en)
|
2013-12-18 |
2017-12-13 |
The California Institute for Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
US10532083B2
(en)
|
2014-02-13 |
2020-01-14 |
Technische Universität München |
Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
|
RU2019119862A
(ru)
|
2014-02-20 |
2019-07-15 |
Аллерган, Инк. |
Антитела к компоненту комплемента c5
|
SG11201606983SA
(en)
|
2014-02-27 |
2016-09-29 |
Allergan Inc |
COMPLEMENT FACTOR Bb ANTIBODIES
|
US20170029366A1
(en)
|
2014-03-07 |
2017-02-02 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
CN111620830A
(zh)
|
2014-03-14 |
2020-09-04 |
北卡罗来纳大学教堂山分校 |
用于抑制雄性生育力的小分子
|
ES2961843T3
(es)
|
2014-04-04 |
2024-03-14 |
Intra Cellular Therapies Inc |
Gamma-carbolinas condensadas con heterociclo deuteradas como antagonistas de los receptores de 5-HT2A
|
WO2015154030A1
(en)
|
2014-04-04 |
2015-10-08 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
US9956164B2
(en)
|
2014-04-16 |
2018-05-01 |
Veyx-Pharma Gmbh |
Veterinary pharmaceutical composition and use thereof
|
WO2015173398A1
(en)
|
2014-05-15 |
2015-11-19 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of slc38a9 and their use in therapy
|
WO2015179415A1
(en)
|
2014-05-19 |
2015-11-26 |
Novartis Ag |
Methods of treating anorexia
|
WO2015184260A2
(en)
|
2014-05-30 |
2015-12-03 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
WO2015187779A1
(en)
|
2014-06-03 |
2015-12-10 |
Xbiotech, Inc. |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
US10179776B2
(en)
|
2014-06-09 |
2019-01-15 |
Intra-Cellular Therapies, Inc. |
Compounds and methods of use to treat schizophrenia
|
BR112016028567A2
(pt)
|
2014-06-09 |
2018-01-30 |
Kyowa Hakko Kirin Co Ltd |
método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea
|
MX2016016281A
(es)
|
2014-06-13 |
2017-03-31 |
Santa Maria Biotherapeutics Inc |
Polipeptidos receptores formulados y metodos relacionados.
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
WO2016007919A2
(en)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
EP2977758A1
(en)
|
2014-07-24 |
2016-01-27 |
Université De Nice Sophia Antipolis |
Methods and kits for monitoring membranous nephropathy
|
TW201609812A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
最佳化之跨物種特異性雙特異性單鏈抗體構築體
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
AU2015301753B2
(en)
|
2014-08-12 |
2021-04-08 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
EA201790434A1
(ru)
|
2014-08-22 |
2017-07-31 |
Окленд Юнисервисиз Лимитед |
Модуляторы каналов
|
CN106714811A
(zh)
|
2014-08-27 |
2017-05-24 |
佩普蒂梅德股份有限公司 |
抗肿瘤组合物和方法
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
BR112017007817A2
(pt)
|
2014-10-21 |
2017-12-19 |
Sciclone Pharmaceuticals Inc |
tratamento do câncer com estimuladores imunológicos
|
MX2017004947A
(es)
|
2014-10-24 |
2017-06-29 |
Bristol Myers Squibb Co |
Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
EP3250609A4
(en)
|
2015-01-26 |
2018-07-11 |
The University of Chicago |
Il13ra alpha 2 binding agents and use thereof in cancer treatment
|
US9744239B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
US10906948B2
(en)
|
2015-02-23 |
2021-02-02 |
Seagull Therapeutics Sas |
Non-natural Semaphorins 3 and their medical use
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
US10851144B2
(en)
|
2015-04-10 |
2020-12-01 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
IL255076B2
(en)
|
2015-04-17 |
2023-10-01 |
Amgen Res Munich Gmbh |
CDH3 and CD3 bispecific antibody constructs
|
US20180146703A1
(en)
*
|
2015-05-15 |
2018-05-31 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
EP3310376A4
(en)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
|
US10676490B2
(en)
|
2015-07-07 |
2020-06-09 |
Florida Southwestern State College |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
ES2546566B2
(es)
*
|
2015-07-23 |
2016-09-14 |
Universidade De Santiago De Compostela |
Sistema para la administración de sustancias biológicamente activas preparado por técnicas de espumado empleando gases comprimidos o fluidos supercríticos
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
EP3328827B1
(en)
|
2015-07-31 |
2023-07-05 |
The Johns Hopkins University |
Prodrugs of glutamine analogs
|
CN108348492B
(zh)
|
2015-07-31 |
2021-09-28 |
约翰霍普金斯大学 |
使用谷氨酰胺类似物的用于癌症和免疫疗法的方法
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
CA2994162A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Glutamine antagonists for the treatment of cognitive deficits
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
EP3355908A1
(en)
|
2015-10-01 |
2018-08-08 |
Amgen Inc. |
Treatment of bile acid disorders
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
KR20180077271A
(ko)
|
2015-11-03 |
2018-07-06 |
암브룩스, 인코포레이티드 |
항-cd3-폴레이트 컨쥬게이트 및 이의 용도
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
ES2961967T3
(es)
|
2015-12-18 |
2024-03-14 |
Talengen Int Ltd |
Plasminógeno para su uso en el tratamiento de la angiocardiopatía diabética
|
CR20180378A
(es)
|
2015-12-23 |
2018-12-06 |
Amgen Inc |
Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
|
EP3395835B1
(en)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
EP3402804A1
(en)
|
2016-01-11 |
2018-11-21 |
Synergy Pharmaceuticals Inc. |
Formulations and methods for treating ulcerative colitis
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
CN108883111B
(zh)
|
2016-01-26 |
2021-10-08 |
细胞内治疗公司 |
有机化合物
|
MD3411402T2
(ro)
|
2016-02-03 |
2022-05-31 |
Amgen Res Munich Gmbh |
Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
|
TN2018000266A1
(en)
|
2016-02-03 |
2020-01-16 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs.
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
JP2019506412A
(ja)
|
2016-02-10 |
2019-03-07 |
ラトガース, ザ ステイト ユニバーシティー オブ ニュージャージー |
結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗−LAMおよび抗−PIM6/LAMモノクローナル抗体
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
MX2018010988A
(es)
|
2016-03-14 |
2019-01-21 |
Chugai Pharmaceutical Co Ltd |
Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
|
AU2017238842B2
(en)
|
2016-03-25 |
2019-06-20 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
EP3808764A1
(en)
|
2016-05-04 |
2021-04-21 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
JP7308034B2
(ja)
|
2016-07-01 |
2023-07-13 |
リゾルブ セラピューティクス, エルエルシー |
最適化二重ヌクレアーゼ融合物および方法
|
US10300145B2
(en)
|
2016-07-15 |
2019-05-28 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
KR20190037261A
(ko)
|
2016-08-08 |
2019-04-05 |
암젠 인크 |
항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
CN109661241A
(zh)
|
2016-09-06 |
2019-04-19 |
中外制药株式会社 |
使用识别凝血因子ix和/或活化凝血因子ix以及凝血因子x和/或活化凝血因子x的双特异性抗体的方法
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
CN109790125B
(zh)
|
2016-09-16 |
2022-07-05 |
研究三角协会 |
四氢异喹啉κ阿片拮抗剂
|
WO2018071233A1
(en)
|
2016-10-12 |
2018-04-19 |
Intra-Cellular Therapies, Inc. |
Amorphous solid dispersions
|
JP7149935B2
(ja)
|
2016-10-19 |
2022-10-07 |
ザ スクリプス リサーチ インスティテュート |
ヒト化された標的化部分および/または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
|
CA3047298C
(en)
|
2016-12-15 |
2023-12-12 |
Talengen International Limited |
Drug for preventing and treating osteoporosis and use thereof
|
CA3046671C
(en)
|
2016-12-15 |
2023-08-08 |
Talengen International Limited |
Method for preventing and treating pulmonary fibrosis
|
WO2018107695A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种预防和治疗肾纤维化的方法
|
US11207387B2
(en)
|
2016-12-15 |
2021-12-28 |
Talengen International Limited |
Method and drug for preventing and treating obesity
|
TW201822812A
(zh)
|
2016-12-15 |
2018-07-01 |
深圳瑞健生命科學硏究院有限公司 |
一種預防和治療肥胖症的方法
|
WO2018107706A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种使胰高血糖素、胰岛素恢复正常平衡的方法
|
TWI677348B
(zh)
|
2016-12-15 |
2019-11-21 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種改善心臟病變的方法
|
US10961245B2
(en)
|
2016-12-29 |
2021-03-30 |
Intra-Cellular Therapies, Inc. |
Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
|
WO2018126143A1
(en)
|
2016-12-29 |
2018-07-05 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
AU2018206279B2
(en)
|
2017-01-06 |
2020-09-03 |
Abl Bio Inc. |
Anti-alpha-syn antibody and use thereof
|
US11529391B2
(en)
|
2017-01-09 |
2022-12-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Reversing deficient hedgehog signaling restores deficient skeletal regeneration
|
US10603358B2
(en)
|
2017-01-10 |
2020-03-31 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
EP4364799A3
(en)
|
2017-01-11 |
2024-07-17 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Mesenchymal stem cell-derived extracellular vesicles and their medical use
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
KR102670432B1
(ko)
|
2017-02-08 |
2024-05-28 |
브리스톨-마이어스 스큅 컴퍼니 |
약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
WO2018160791A1
(en)
|
2017-03-03 |
2018-09-07 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
US10421968B2
(en)
|
2017-03-15 |
2019-09-24 |
Versitech Limited |
Amphiphilic dendrimers complexed with siRNA for treatment of cancer
|
IL268970B2
(en)
|
2017-03-24 |
2023-12-01 |
Intra Cellular Therapies Inc |
Oral preparations of heterocyclic gamma carboline derivatives fused for absorption through mucous membranes
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
JP7384672B2
(ja)
|
2017-05-04 |
2023-11-21 |
ヘルシンギン ユリオピスト |
C末端cdnf断片及びc末端manf断片、それらを含む医薬組成物、並びにそれらの使用
|
BR112019022751A2
(pt)
|
2017-05-05 |
2020-05-19 |
Amgen Inc |
composição farmacêutica compreendendo construtos de anticorpos biespecíficos para armazenamento e administração melhorados
|
JP7283699B2
(ja)
|
2017-05-12 |
2023-05-30 |
マックス-プランク-ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
黒色腫の治療または予防において使用するためのフェニル-ヘテロ環-フェニル誘導体
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
US11938172B2
(en)
|
2017-06-19 |
2024-03-26 |
Talengen International Limited |
Method for regulating and controlling GLP-1/GLP-1R and drug
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
KR20200019122A
(ko)
|
2017-06-20 |
2020-02-21 |
암젠 인크 |
Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
WO2019018691A1
(en)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
MODULATION OF CYTOKINE
|
WO2019023063A1
(en)
|
2017-07-26 |
2019-01-31 |
Intra-Cellular Therapies, Inc. |
ORGANIC COMPOUNDS
|
JP7223742B2
(ja)
|
2017-07-26 |
2023-02-16 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
有機化合物
|
CN111164104A
(zh)
|
2017-08-09 |
2020-05-15 |
麻省理工学院 |
白蛋白结合肽缀合物及其方法
|
US11485781B2
(en)
|
2017-08-17 |
2022-11-01 |
Massachusetts Institute Of Technology |
Multiple specificity binders of CXC chemokines
|
CN111315767A
(zh)
|
2017-08-22 |
2020-06-19 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
CN111148533A
(zh)
|
2017-09-19 |
2020-05-12 |
麻省理工学院 |
用于嵌合抗原受体t细胞疗法的组合物及其用途
|
EA202090581A1
(ru)
|
2017-10-04 |
2020-08-31 |
Амген Инк. |
Продукты слияния транстиретина и иммуноглобулина
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
WO2019089365A1
(en)
|
2017-10-30 |
2019-05-09 |
Enterin Laboratories, Inc. |
New squalamine solid forms and methods of making the same
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
EA202091422A1
(ru)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
Способ непрерывного производства продуктов на основе биспецифических антител
|
WO2019114839A1
(zh)
|
2017-12-15 |
2019-06-20 |
泰伦基国际有限公司 |
一种预防或治疗骨关节炎的方法和药物
|
CA3086205A1
(en)
|
2017-12-19 |
2019-06-27 |
Massachusetts Institute Of Technology |
Antigen-adjuvant coupling reagents and methods of use
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
BR112020016144A2
(pt)
|
2018-02-09 |
2020-12-15 |
Nestlé Skin Health Sa |
Nemolizumabe no tratamento de dermatite atópica com escoriação moderada a grave
|
KR20230020023A
(ko)
|
2018-03-14 |
2023-02-09 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
WO2019178484A1
(en)
|
2018-03-16 |
2019-09-19 |
Intra-Cellular Therapies, Inc. |
Novel methods
|
JP7328983B2
(ja)
|
2018-03-22 |
2023-08-17 |
サーフィス オンコロジー インコーポレイテッド |
抗il-27抗体及びその使用
|
WO2019183341A1
(en)
|
2018-03-23 |
2019-09-26 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP3774858A1
(en)
|
2018-03-29 |
2021-02-17 |
Helsingin Yliopisto |
C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof
|
SG11202008206TA
(en)
|
2018-03-30 |
2020-09-29 |
Amgen Inc |
C-terminal antibody variants
|
AU2019253462A1
(en)
|
2018-04-09 |
2020-11-26 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
AU2019255370B2
(en)
|
2018-04-19 |
2023-11-02 |
Checkmate Pharmaceuticals, Inc. |
Synthetic RIG-I-like receptor agonists
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
AU2019272575A1
(en)
|
2018-05-21 |
2020-12-10 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by NK cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
WO2019237037A1
(en)
|
2018-06-08 |
2019-12-12 |
Intra-Cellular Therapies, Inc. |
Novel methods
|
EP3609891A4
(en)
|
2018-06-11 |
2021-04-14 |
Intra-Cellular Therapies, Inc. |
SYNTHESIS OF CONDENSED GAMMA CARBOLINE WITH SUBSTITUTED HETEROCYCLE
|
WO2020011938A1
(en)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoids for the topical treatment of autoimmune gastritis
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
BR112021003843A2
(pt)
|
2018-08-28 |
2021-05-25 |
Ambrx, Inc. |
biconjugados de folato de anticorpo anti-cd3 e seus usos
|
CN112584837A
(zh)
|
2018-08-31 |
2021-03-30 |
细胞内治疗公司 |
新方法
|
KR20210052472A
(ko)
|
2018-08-31 |
2021-05-10 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
신규한 방법
|
KR20210057124A
(ko)
|
2018-09-11 |
2021-05-20 |
암브룩스, 인코포레이티드 |
인터류킨-2 폴리펩타이드 접합체 및 그의 용도
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
JP2022502037A
(ja)
|
2018-09-28 |
2022-01-11 |
マサチューセッツ インスティテュート オブ テクノロジー |
コラーゲンに局在化される免疫調節分子およびその方法
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
BR112021013096A2
(pt)
|
2019-01-04 |
2022-04-19 |
Resolve Therapeutics, Llc |
Tratamento de doença de sjögren com proteínas de fusão de nuclease
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
EP3914289A1
(en)
|
2019-01-23 |
2021-12-01 |
Massachusetts Institute of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
AU2020223031A1
(en)
|
2019-02-12 |
2021-08-19 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-TLR agonist conjugates
|
EP3941511A2
(en)
|
2019-03-20 |
2022-01-26 |
Massachusetts Institute of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
US20220220210A1
(en)
|
2019-03-29 |
2022-07-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
|
JP7501876B2
(ja)
|
2019-04-17 |
2024-06-18 |
国立大学法人広島大学 |
Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
|
EP3967322A4
(en)
|
2019-05-10 |
2022-06-08 |
Talengen International Limited |
METHOD AND MEDICATION FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
|
EP3978018A4
(en)
|
2019-05-31 |
2023-07-19 |
Osaka University |
NEW THERAPEUTIC AGENT AGAINST DIGESTIVE CANCERS, AND ASSOCIATED SCREENING METHOD
|
EP4023230A4
(en)
|
2019-06-05 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIBODY CLEAVAGE SITE BINDING MOLECULE
|
US20220348658A1
(en)
|
2019-06-10 |
2022-11-03 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
CN114072150A
(zh)
|
2019-07-07 |
2022-02-18 |
细胞内治疗公司 |
新方法
|
MX2021015976A
(es)
|
2019-07-08 |
2022-02-10 |
Amgen Inc |
Fusiones de inmunoglobulina y transtiretina multiespecificas.
|
CR20220049A
(es)
|
2019-07-10 |
2022-03-02 |
Chugai Pharmaceutical Co Ltd |
Moléculas de unión a claudina-6 y usos de las mismas
|
WO2021021676A1
(en)
|
2019-07-26 |
2021-02-04 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
EP4385573A2
(en)
|
2019-08-13 |
2024-06-19 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
US20220372160A1
(en)
|
2019-09-16 |
2022-11-24 |
Surface Oncology, Inc. |
Anti-CD39 Antibody Compositions and Methods
|
KR20220066346A
(ko)
|
2019-09-25 |
2022-05-24 |
서피스 온콜로지, 인크. |
항-il-27 항체 및 이의 용도
|
WO2021070885A1
(ja)
|
2019-10-11 |
2021-04-15 |
中外製薬株式会社 |
後天性血友病aの予防および/または治療に用いられる医薬組成物、および当該医薬組成物を含む製品
|
WO2021081353A1
(en)
|
2019-10-23 |
2021-04-29 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
WO2021081440A2
(en)
|
2019-10-24 |
2021-04-29 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
METHOD FOR REDUCING AGGREGATE FORMATION IN DOWNSTREAM PROCESSING OF BI-SPECIFIC ANTIGEN-BINDING MOLECULES
|
JP2023502794A
(ja)
|
2019-11-19 |
2023-01-25 |
モダグ ゲーエムベーハー |
α-シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物
|
WO2021119334A1
(en)
|
2019-12-11 |
2021-06-17 |
Intra-Cellular Therapies, Inc. |
Organic compound
|
CA3162705A1
(en)
|
2019-12-17 |
2021-06-24 |
Amgen Inc. |
Dual interleukin-2 /tnf receptor agonist for use in therapy
|
EP3838912A1
(en)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Retro-inverso peptides
|
EP3838345A1
(en)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Macrocyclic peptides
|
AU2021205877B2
(en)
|
2020-01-06 |
2024-06-20 |
Vaccinex, Inc. |
Anti-CCR8 antibodies and uses thereof
|
CA3167217A1
(en)
|
2020-01-13 |
2021-07-22 |
Durect Corporation |
Sustained release drug delivery systems with reduced impurities and related methods
|
WO2021143906A1
(zh)
|
2020-01-17 |
2021-07-22 |
泰伦基国际有限公司 |
一种治疗神经损伤及其相关病症的方法
|
CN115427066A
(zh)
|
2020-02-06 |
2022-12-02 |
泰伦基国际有限公司 |
一种预防和治疗多发性硬化症的方法和药物
|
CN115605219A
(zh)
|
2020-02-11 |
2023-01-13 |
泰伦基国际有限公司(Hk) |
一种治疗病毒性肺炎的方法和药物
|
US20230139956A1
(en)
|
2020-02-26 |
2023-05-04 |
Talengen International Limited |
Method and drug for preventing and treating abnormal blood pressure condition
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
CN115243726A
(zh)
|
2020-03-11 |
2022-10-25 |
北京泰德制药股份有限公司 |
白介素-2多肽偶联物及其使用方法
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
WO2021190561A1
(zh)
|
2020-03-24 |
2021-09-30 |
泰伦基国际有限公司 |
一种治疗帕金森病的方法和药物
|
US20230173039A1
(en)
|
2020-03-24 |
2023-06-08 |
Talengen International Limited |
Method and drug for treating alzheimer disease
|
TWI787767B
(zh)
|
2020-03-24 |
2022-12-21 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種治療亨廷頓病的方法和藥物
|
JP2023518564A
(ja)
|
2020-03-24 |
2023-05-02 |
タレンゲン インターナショナル リミテッド |
ミスフォールドタンパク質およびその凝集体の分解を促進する方法及び薬剤
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
EP4140498A4
(en)
|
2020-05-11 |
2023-11-01 |
Talengen International Limited |
METHOD AND MEDICINE FOR THE TREATMENT OF SPINAL AMYOTROPHY
|
EP4161520A1
(en)
|
2020-06-05 |
2023-04-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
US20230235056A1
(en)
|
2020-06-19 |
2023-07-27 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
MX2023001120A
(es)
|
2020-07-31 |
2023-02-22 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
|
EP4199968A1
(en)
|
2020-08-20 |
2023-06-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
EP4203999A1
(en)
|
2020-08-26 |
2023-07-05 |
Scancell Limited |
Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
|
WO2022081436A1
(en)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022096716A2
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
TW202222337A
(zh)
|
2020-11-17 |
2022-06-16 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種提高bdnf水平的方法和藥物
|
CN116490200A
(zh)
|
2020-11-17 |
2023-07-25 |
泰伦基国际有限公司 |
一种提高ngf水平的方法和药物
|
EP4294834A2
(en)
|
2021-02-19 |
2023-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Single domain antibodies that neutralize sars-cov-2
|
CN117320749A
(zh)
|
2021-03-12 |
2023-12-29 |
中外制药株式会社 |
用于治疗或预防重症肌无力的药物组合物
|
MX2023011480A
(es)
|
2021-04-03 |
2023-12-06 |
Ambrx Inc |
Conjugados anticuerpo anti-her2-fármaco y usos de estos.
|
JP2024517759A
(ja)
|
2021-04-28 |
2024-04-23 |
ミノトール セラピューティクス インコーポレイテッド |
ヒト化キメラウシ抗体および使用方法
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
EP4334348A1
(en)
|
2021-05-07 |
2024-03-13 |
Surface Oncology, LLC |
Anti-il-27 antibodies and uses thereof
|
KR20240035394A
(ko)
|
2021-05-14 |
2024-03-15 |
클라리스 바이오쎄라퓨틱스, 인코포레이티드 |
안질환 치료를 위한 성장 인자 조성물
|
TW202323276A
(zh)
|
2021-09-03 |
2023-06-16 |
瑞士伯恩大學 |
用於治療長qt症候群之組成物及方法
|
WO2023053282A1
(ja)
|
2021-09-29 |
2023-04-06 |
中外製薬株式会社 |
がんの治療に用いるための細胞傷害誘導治療剤
|
KR20240099407A
(ko)
|
2021-11-03 |
2024-06-28 |
아피메트 게엠베하 |
이중특이적 cd16a 결합제
|
IL312060A
(en)
|
2021-11-03 |
2024-06-01 |
Affimed Gmbh |
Bispecific CD16A binders
|
US20230364031A1
(en)
|
2022-04-19 |
2023-11-16 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023225620A1
(en)
|
2022-05-18 |
2023-11-23 |
Intra-Cellular Therapies, Inc. |
Novel methods
|
WO2023230116A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
WO2024047497A1
(en)
|
2022-09-02 |
2024-03-07 |
Galderma Holding SA |
Treatments for prurigo nodularis
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|
WO2024121796A1
(en)
|
2022-12-07 |
2024-06-13 |
Fondazione Matilde Tettamanti E Menotti De Marchi Onlus |
Methods for generating genetically modified cytokine induced killer (cik) cells
|
CN115804830A
(zh)
*
|
2022-12-16 |
2023-03-17 |
浙江圣兆药物科技股份有限公司 |
一种缩短迟滞期的戈舍瑞林缓释植入剂
|
WO2024145659A1
(en)
|
2022-12-30 |
2024-07-04 |
Intra-Cellular Therapies, Inc. |
Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
|